(P098) Dosimetric Predictors of Pulmonary Toxicity in Patients With Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Sparing the ipsilateral lung of at least a finite functional unit per 1 L of the ipsilateral lung is a predictor of the development of radiation pneumonitis. This represents a new dosimetric measure in plan evaluation and correlates significantly with the development of toxicity in patients with malignant pleural mesothelioma receiving radiation to the ipsilateral lung. This factor might be a more effective and useful parameter in these challenging cases.

Yaseen Zia, MD, Vishruta Dumane, PhD, Kenneth Rosenzweig; Icahn School of Medicine at Mount Sinai

INTRODUCTION: Pleurectomy and decortication is gaining wider acceptance as a standard surgery for malignant pleural mesothelioma. Adjuvant radiation is particularly challenging, due to the need to treat the pleura while sparing the underlying intact lung. Typical dosimetric constraints are of limited value in this patient population. This study aimed to establish whether there was a functional subunit of lung that needed to be spared that was predictive of development of radiation pneumonitis in patients with malignant pleural mesothelioma receiving radiation therapy to the intact lungs.

MATERIALS AND METHODS: A total of 18 patients with malignant pleural mesothelioma (MPM) were treated with definitive or adjuvant hemithoracic pleural intensity-modulated radiation therapy (IMRT) after radical pleurectomy and decortification between 2010 and 2014. The dose was prescribed to the planning target volume (PTV), which included the entire parietal and visceral pleura, with a median dose of 4,500 cGy (range: 3,000–5,940 cGy). Specific dosimetric parameters pertaining to both lungs were recorded. Toxicity was assessed during weekly on-treatment visits and in follow-up examinations using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0) criteria.

RESULTS: The median follow-up was 4 months (range: 1–18 mo). Six patients (33%) developed grade 3 pneumonitis or higher, and 12 patients (67%) did not. Mean lung dose and V30 of the total lungs were found to be statistically significant for the development of pneumonitis. Contralateral lung V5 and mean lung dose were found not to correlate with the development of pneumonitis, in contrast to previously published reports. We found that for each 1,000 cc of ipsilateral lung, if 150 cc was treated to less than 20 Gy, there was significantly less pneumonitis. No patients with 150 cc spared per 1,000 cc of normal lung developed pneumonitis vs 43% (6 of 14) of patients who failed to reach that threshold (P < .05).

CONCLUSIONS: Sparing the ipsilateral lung of at least a finite functional unit per 1 L of the ipsilateral lung is a predictor of the development of radiation pneumonitis. This represents a new dosimetric measure in plan evaluation and correlates significantly with the development of toxicity in patients with malignant pleural mesothelioma receiving radiation to the ipsilateral lung. This factor might be a more effective and useful parameter in these challenging cases.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.
Survivors of cancer may experience an increased risk of having organ, cardiac, or lung disease following prior anti-cancer therapy.
Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.
The development of RAS-directed vaccines may help decrease the likelihood of disease recurrence in patients undergoing treatment for pancreatic cancer.
Related Content